It is made available under a [CC-BY-ND 4.0 International license](http://creativecommons.org/licenses/by-nd/4.0/) .

¹⁸ F-NaF Uptake on Vascular PET Imaging in Symptomatic versus Asymptomatic

Atherosclerotic Disease: a Meta-Analysis

- 3 Bhakta S¹, Chowdhury MM², Tarkin JM³, Rudd JHF³, Warburton EA¹, Evans NR¹
-
- $10¹$ Department of Clinical Neurosciences, University of Cambridge, Cambridge. CB2 0QQ
- ² Department of Vascular Surgery, University of Cambridge, Cambridge. CB2 0QQ
- ³ Division of Cardiovascular Medicine, University of Cambridge, Cambridge. CB2 0QQ
-
- Corresponding author:
- Nicholas Evans
- R3 Clinical Neurosciences
- Addenbrooke's Hospital
- Cambridge
- CB2 0QQ
-
- Email: ne214@cam.ac.uk
- 17 Twitter: @nr_evans
-
- Word count: 6634
-

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

It is made available under a [CC-BY-ND 4.0 International license](http://creativecommons.org/licenses/by-nd/4.0/) . perpetuity. preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in medRxiv preprint doi: [https://doi.org/10.1101/2024.02.22.24303229;](https://doi.org/10.1101/2024.02.22.24303229) this version posted February 23, 2024. The copyright holder for this

Abstract

Introduction

 F-sodium fluoride (NaF) positron-emission tomography (PET) is increasingly being used to measure microcalcification in atherosclerotic disease *in vivo*. Correlations have been drawn 27 between sodium fluoride uptake and the presence of high-risk plaque features, as well as its 28 association with clinical atherosclerotic sequelae. The aim of this review was to perform a meta-analysis of NaF uptake on PET imaging and its relation to symptomatic and asymptomatic disease.

Methods

 A systematic review was performed according to PRISMA guidelines, via searching the MEDLINE database up to August 2023. The search strategy included the terms "NaF", "PET" and "plaque", and all studies were included where there was data listed regarding the degree of microcalcification, as measured by 18 F-NaF uptake in symptomatic and asymptomatic atherosclerotic plaques. Analysis involved calculating standardized mean differences between uptake values and comparison using a random-effects model. Results A total of 15 articles, involving 423 participants, were included in the meta-analysis. 44 Comparing F-NaF uptake in symptomatic vs asymptomatic atherosclerotic plaques, a 45 standardized mean difference of 0.42 (95% CI 0.29-0.56; p<0.001, $I^2 = 54.1\%$) was noted for

those studies comparing symptomatic and asymptomatic plaques in the same participant,

- 47 with no significant change in effect based on arterial territory studied (Q_M = 5.02, p = 0.08).
- In those studies where data was included from participants with and without symptomatic

disease, the standardized mean difference between symptomatic and asymptomatic

50 plaques was 0.44 (95% CI 0.03-0.85, p=0.037, I^2 = 40.4%). All studies including asymptomatic

- participants were investigating carotid disease.
-

53 Conclusions

54

- 55 PET imaging using ¹⁸F-NaF can detect differences in microcalcification between symptomatic
- 56 and asymptomatic atherosclerotic plaques within and between individuals, and is a marker
- 57 of symptomatic disease. The standardization of ¹⁸F-NaF PET imaging protocols, and its future
- 58 use as a risk stratification tool or outcome measure, requires further study.
- 59

It is made available under a [CC-BY-ND 4.0 International license](http://creativecommons.org/licenses/by-nd/4.0/) .

Non-standard Abbreviations and Acronyms

MDS – most diseased segment

- NaF sodium fluoride
- ROI region of interest
- SUV standardized uptake value
- TBR tissue-to-background ratio
- TBRmax maximum tissue-to-background ratio from the region of interest

68 **Introduction**

69

 Atherosclerosis is a systemic chronic arterial disease¹, involving the accumulation of lipids 71 and inflammatory cells² to form foci of disease, termed 'plaques', at the vessel wall. It is the cause of over one third of all deaths³, through resulting diseases such as myocardial infarction, ischemic stroke, and critical limb threatening ischemia. In some patients, minor or less severe clinical symptoms may be a marker of higher risk for progressing to more 75 severe clinical disease, such as stable angina preceding myocardial infarction^{4,5}, or transient ischemic attack, conferring a higher risk of ischemic stroke in the short term^{6,7}. 77

 78 Plaques may have heterogenous appearances⁸, with certain plaque features indicating a 79 higher risk of rupture and subsequent clinical sequelae^{8,9}. These high-risk features include 80 the presence of a lipid-rich necrotic core¹⁰, intraplaque hemorrhage¹¹, a thin or ruptured 81 fibrous cap¹², and the presence of microcalcification¹³. The mechanisms determining the 82 transition from a low-risk ("stable") to a high-risk ("unstable") plaque and vice versa are 83 incompletely understood^{14,15}, but microcalcification has been recognized as a potential 84 cause for acute plaque rupture, through mechanical destabilization of the fibrous cap of the 85 plaque¹⁶, as well as causing an increased inflammatory response within the plaque¹⁷, leading 86 to enzymatic destabilization of the plaque¹⁸. Microcalcifications are calcium deposits of 87 <50µm in diameter, which is below the spatial resolution of commonly-used clinical vascular 88 imaging techniques¹⁹, such as computed tomography (CT) or magnetic resonance imaging 89 (MRI).

90

 Positron emission tomography (PET) is a nuclear imaging technique used in vascular imaging due to its high sensitivity to detect low concentrations of radiolabeled ligands (termed "tracers"), which can be directed to detect the presence of a specific target or process²⁰. Sodium fluoride (NaF), labelled with fluorine-18, has been validated as a tracer for the 95 identification of microcalcification in vascular imaging²¹.

96

97 NaF adsorbs to the surface of hydroxyapatite within the body²², with hydroxyapatite being 98 the most common calcium-containing crystal structure in atherosclerotic plaques *in vivo*^{23,24}. 99 Fluorine exchanges with hydroxyl groups on the surface of these crystals, while there is

 substantially less tracer uptake deeper within the crystal structure of the molecule²². Calcium deposits with an increased surface area therefore have increased fluoride ion 102 uptake over the uptake durations used in clinical PET scanning^{22,25}. Using NaF, this process of hydroxyl-ion substitution can be used to detect microcalcifications via PET imaging. Due to their high surface area to volume ratio, microcalcifications will demonstrate higher uptake on PET compared to areas with no microcalcification, or those with larger deposits of 106 calcium ("macrocalcification")²⁶⁻²⁸. NaF-PET can be preferred for vascular imaging compared to other PET imaging techniques for visualizing high-risk plaques due to issues, such as 'spill- over artefact' when using fluorodeoxyglucose (FDG)-PET in cardiac imaging. There is an increasing body of literature demonstrating the use of NaF-PET for vascular imaging in atherosclerosis²⁹, and specifically, in symptomatic disease. This meta-analysis focuses on the role of NaF-PET imaging to differentiate between symptomatic versus asymptomatic atherosclerotic disease. **Methods**

Protocol, Search Strategy and Selection Criteria

119 Details for the protocol were registered on PROSPERO. The selection process and 120 reporting items were based on the preferred reporting items for systematic reviews and 121 meta-analysis (PRISMA) flow diagram and checklist³¹. The primary outcome was to determine differences in NaF tracer uptake between symptomatic and asymptomatic atherosclerotic plaques. A search strategy was formulated using Embase and Medline All via Ovid (**Figure 1**). Additionally, a manual search was performed to identify relevant records through reference searches. Duplicate records were removed, and the retrieved records were checked for inclusion and exclusion criteria.

 Studies were eligible for inclusion if they investigated the association between NaF uptake and symptomatic and asymptomatic atherosclerotic plaques, where symptomatic plaques were those that were associated with a recent clinical vascular event, including, but not limited to, stroke or myocardial infarction, while asymptomatic plaques were those not

It is made available under a [CC-BY-ND 4.0 International license](http://creativecommons.org/licenses/by-nd/4.0/) . perpetuity. preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in medRxiv preprint doi: [https://doi.org/10.1101/2024.02.22.24303229;](https://doi.org/10.1101/2024.02.22.24303229) this version posted February 23, 2024. The copyright holder for this

- associated with a recent clinical vascular event. Studies were excluded if animal data was
- used, non-atherosclerotic disease was investigated, or if the study did not provide details
- regarding the type or location of symptomatic disease.
-

Data Selection, Extraction and Quality Assessment

-
- Data were extracted by one study investigator (S. B.) and checked by another researcher (N.
- R. E.), from the included records, using a standardized electronic data collection form.
- Discrepancies were resolved by re-extraction or by third-party adjudication (E. A. W.) as
- required. Retrieved characteristics from the studies included, but was not limited to, the
- number of subjects, patient population, targeted vascular territory, dose of NaF injected,
- uptake time, imaging protocols, primary endpoint measures for PET/CT and main findings,
- 144 which were tabulated as per published guidance³². The ROBINS-E tool³³ was used to assess
- the quality of the studies included in this review (**Supplementary Figure 1)**.
-

Statistical Analysis

 The mean and associated standard deviation (SD), or the median and the associated interquartile range (IQR) of the measurement of NaF signal were extracted from the included studies. Extracted median and IQR data was converted into mean and SD data in order to calculate a unified outcome³⁴. In studies where multiple measures of NaF signal 153 were listed, the value corresponding to the TBR related to the maximum SUV value (TBR_{max}) was taken. The absolute difference between the populations when NaF signal is measured using SUV versus TBR is minor, given the low blood pool activity of NaF following an 156 appropriate uptake time¹⁹.

 Studies were classified by their included participants – those with only symptomatic participants, or those also including an asymptomatic control population. The effect estimates from each study were pooled using the inverse-variance weighted method, and 161 random effects models were used for meta-analysis. l^2 statistics were calculated to determine the variability in effect estimate due to between-study heterogeneity. Meta-analyses were performed where there were two or more studies using the same type of

 included population. Standardized mean differences were calculated due to the variability in reporting outcomes used in the included studies.

Funnel plots (**Figures 2 and 3)** were used to visually assess the symmetry of the studies

about the mean effect size, to identify any publication bias. Two-tailed tests were used, and

a *p*-value of 0.05 was taken as the limit of statistical significance. Statistical analyses were

170 performed using the *metafor*³⁵ and *metamedian*³⁶ packages, using R Statistical Software

(v4.3.1, R Core Team 2023).

Subgroup analysis was performed between the different arterial territories assessed in the

included studies to generate standardized mean difference measurements for symptomatic

atherosclerotic plaques compared with asymptomatic plaques, and to determine any

statistical differences in NaF uptake between different arterial territories.

-
- **Results**
-

Included Studies

182 A total of 966 titles were initially identified from the search (Figure 4)³⁷. Manual de- duplication of results was performed, and the remaining 733 records underwent manual 184 screening of the titles and abstracts³⁸. Of those, 636 were excluded as not meeting the inclusion criteria. 97 articles were therefore sought for retrieval. Five articles were not available for analysis and 92 articles were therefore assessed for eligibility through full-text review. Of these, 77 were excluded, 53 due to not reporting outcomes related to symptomatic atherosclerotic disease, 15 due to no documented comparison between symptomatic and asymptomatic disease, eight due to discussion of imaging protocols and quality assessment and one due to reporting outcome measures insufficient for meta- analysis. The remaining 15 articles were included in the meta-analysis, and form the study population analyzed. A summary of study details is shown in **Tables 1 and 2**, dichotomized based on the comparator of symptomatic disease used in each study.

227 **Discussion**

228

229 These results demonstrate the utility of NaF-PET, combined with CT or MRI, to differentiate 230 between symptomatic and asymptomatic atherosclerotic disease in a number of different 231 vascular territories. Studies have also demonstrated a correlation between NaF uptake and 232 high-risk morphological features on MRI, such as the presence of a lipid-rich necrotic core, 233 or intraplaque haemorrhage³⁹. In addition, there is emerging evidence of a prognostic link 234 between NaF signal on PET and the risk of recurrent disease⁴⁰, where coronary NaF imaging 235 had the ability to predict myocardial infarction and cardiovascular death. 236

 As noted in **Tables 1 and 2**, there are a range of different doses of NaF used, along with a non-standardized uptake time, blood pool measurement for TBR calculations, and outcome 239 measurement. Irkle et al²⁵ demonstrated an optimum uptake time of around 60 minutes, based on *in vitro* and *in vivo* data. However, NaF-PET lacks a consensus on best practice, in contrast to vascular FDG-PET imaging, following the 2005 position paper from the European 242 Association of Nuclear Medicine⁴¹. Having a standardized methodology for performing and analyzing vascular NaF imaging would allow increased comparability and reproducibility between studies.

245

246 There was also significant heterogeneity in the included studies between the time of 247 symptom onset and imaging being performed. There is little data concerning the temporal 248 changes in microcalcification and NaF uptake following an acute atherosclerotic event, and 249 further information on the optimum time period for imaging microcalcification in relation to 250 symptomatic disease could further standardize imaging protocols and improve robustness 251 of outcomes measured using NaF-PET as a surrogate marker.

252

253 In atherosclerosis, PET has been demonstrated to have a high sensitivity for the target 254 pathophysiology and can be combined with other imaging modalities to provide additional 255 utility, such as in combination with CT and CT angiography to assess for stenotic disease⁴² 256 and calcium scores in the coronary vasculature⁴³, or with MRI, to identify high risk 257 appearances as discussed above⁴⁴. In vascular imaging, NaF may be superior to FDG as it 258 may have a superior ability to discriminate between symptomatic and asymptomatic disease 259 in high-risk individuals⁴⁵. In addition, NaF does not require fasting prior to the uptake 260 period, and can be used with a shorter uptake time compared to FDG-PET^{25,41}. NaF is also 261 less susceptible to spill-over artefact, such as from the myocardium, which can limit FDG-262 based PET imaging of the arteries⁴⁵. However, the cost, radiation exposure and uptake and 263 scanning time mean the role of PET imaging in routine clinical assessment of atherosclerotic 264 disease is currently limited.

265

266 Microcalcification is known to confer an increased risk of plaque rupture through 267 enzymatic¹⁸ and mechanical¹⁷ destabilization of the plaque surface. Therefore, targeting this 268 process may reduce the risk of early recurrence following symptomatic atherosclerotic 269 disease. NaF-PET can be utilized to assess responses to clinical interventions, given its 270 accuracy and sensitivity in determining differences in the presence of microcalcification *in* 271 *vivo*⁴⁶. Additionally, the process by which microcalcification evolves into macrocalcification, 272 which is thought to be protective for the atherosclerotic plaque, is poorly defined and 273 understood⁴⁷. Temporal evaluation of the microcalcification-macrocalcification process 274 through NaF-PET/CT could shed more light on the factors which confer a greater or lesser 275 degree of risk with calcification in atherosclerosis. In addition, NaF imaging could potentially 276 have a role in risk stratification in patients where there is uncertainty about the risk of 277 recurrent stroke or the need for surgical intervention, which is particularly relevant for 278 those with moderate 50-69% stenoses.

279

280 **Conclusion**

281

 Our findings support vascular NaF-PET imaging as a reliable method for assessment of atherosclerotic disease that is able to help differentiate between symptomatic/vulnerable plaques and asymptomatic/stable plaques. The majority of data involves analysis of the carotid or coronary circulation, but NaF-PET imaging is also a viable imaging technique in other arterial territories. There is a potential future role of NaF-PET in clinical atherosclerosis imaging and providing surrogate markers of impact in interventional trials, 288 but harmonization of imaging protocols including outcome measures, injected doses and uptake times is required to ensure comparability between studies.

290

Funding

-
- SB is supported by a Research Training Fellowship from The Dunhill Medical Trust
- [JBGS22\20]. The ICARUSS study was supported as part of a Research Training Fellowship
- awarded to NRE by The Dunhill Medical Trust [RTF44/0114], and by the NIHR Cambridge
- Biomedical Research Centre (NIHR203312). MC is supported by a BHF Career Development
- Fellowship and the NIHR. JMT is supported by a Wellcome Trust Clinical Research Career
- Development Fellowship (211100/Z/18/Z) and the Cambridge BHF Centre for Research
- Excellence (18/1/34212). JHFR is part-supported by the NIHR Cambridge Biomedical
- Research Centre, the British Heart Foundation, HEFCE, the EPSRC and the Wellcome Trust.
- NRE is supported by a Stroke Association Senior Clinical Lectureship [SA-SCL-MED-
- 22\100006].
-
- **Disclosures**
-
- None
- 1. Libby P, Buring JE, Badimon L, Hansson GK, Deanfield J, Bitencourt MS, Tokgözoğlu L, Lewis EF. Atherosclerosis. *Nature Reviews Disease Primers*. 2019;5:56. doi: 10.1038/s41572-019-0106-z
- 2. Jebari-Benslaiman S, Galicia-García U, Larrea-Sebal A, Olaetxea JR, Alloza I, Vandenbroeck K, Benito-Vicente A, Martín C. Pathophysiology of Atherosclerosis. *Int J Mol Sci*. 2022;23. doi: 10.3390/ijms23063346
- 3. Timmis A, Vardas P, Townsend N, Torbica A, Katus H, De Smedt D, Gale CP, Maggioni AP, Petersen SE, Huculeci R, et al. European Society of Cardiology: cardiovascular disease statistics 2021. *European Heart Journal*. 2022;43:716-799. doi: 10.1093/eurheartj/ehab892
- 4. Eisen A, Bhat DL, Steg PG, Eagle KA, Goto S, Guo J, Smith SC, Ohman EM, Scirica BM. Angina and Future Cardiovascular Events in Stable Patients With Coronary Artery Disease: Insights From the Reduction of Atherothrombosis for Continued Health (REACH) Registry. *J Am Heart Assoc*. 2016;5. doi: 10.1161/jaha.116.004080
- 5. Kannel WB, Feinleib M. Natural history of angina pectoris in the Framingham study. Prognosis and survival. *Am J Cardiol*. 1972;29:154-163. doi: 10.1016/0002- 9149(72)90624-8
- 6. Rothwell PM, Warlow CP. Timing of TIAs preceding stroke: time window for prevention is very short. *Neurology*. 2005;64:817-820. doi: 10.1212/01.Wnl.0000152985.32732.Ee
- 7. Johansson E, Cuadrado-Godia E, Hayden D, Bjellerup J, Ois A, Roquer J, Wester P, Kelly PJ. Recurrent stroke in symptomatic carotid stenosis awaiting revascularization: A pooled analysis. *Neurology*. 2016;86:498-504. doi: 10.1212/wnl.0000000000002354
- 8. Insull W. The Pathology of Atherosclerosis: Plaque Development and Plaque Responses to Medical Treatment. *The American Journal of Medicine*. 2009;122:S3- S14. doi: htps://doi.org/10.1016/j.amjmed.2008.10.013
- 9. Finn AV, Nakano M, Narula J, Kolodgie FD, Virmani R. Concept of Vulnerable/Unstable Plaque. *Arteriosclerosis, Thrombosis, and Vascular Biology*. 2010;30:1282-1292. doi: 10.1161/ATVBAHA.108.179739
- 10. Fleg JL, Stone GW, Fayad ZA, Granada JF, Hatsukami TS, Kolodgie FD, Ohayon J, Pettigrew R, Sabatine MS, Tearney GJ, et al. Detection of high-risk atherosclerotic

> plaque: report of the NHLBI Working Group on current status and future directions. *JACC Cardiovasc Imaging*. 2012;5:941-955. doi: 10.1016/j.jcmg.2012.07.007

- 11. Deng F, Mu C, Yang L, Li H, Xiang X, Li K, Yang Q. Carotid plaque magnetic resonance imaging and recurrent stroke risk: A systematic review and meta-analysis. *Medicine (BalHmore)*. 2020;99:e19377. doi: 10.1097/md.0000000000019377
- 12. Redgrave JN, Gallagher P, Lovett JK, Rothwell PM. Critical cap thickness and rupture in symptomatic carotid plaques: the oxford plaque study. *Stroke*. 2008;39:1722-1729. doi: 10.1161/strokeaha.107.507988
- 13. Vancheri F, Longo G, Vancheri S, Danial JSH, Henein MY. Coronary Artery Microcalcification: Imaging and Clinical Implications. *Diagnostics (Basel)*. 2019;9. doi: 10.3390/diagnostics9040125
- 14. Fox KAA, Metra M, Morais J, Atar D. The myth of 'stable' coronary artery disease. *Nature Reviews Cardiology*. 2020;17:9-21. doi: 10.1038/s41569-019-0233-y
- 15. Akers EJ, Nicholls SJ, Di Bartolo BA. Plaque Calcification. *Arteriosclerosis, Thrombosis, and Vascular Biology*. 2019;39:1902-1910. doi: 10.1161/ATVBAHA.119.311574
- 16. Shi X, Gao J, Lv Q, Cai H, Wang F, Ye R, Liu X. Calcification in Atherosclerotic Plaque Vulnerability: Friend or Foe? *Frontiers in Physiology*. 2020;11. doi: 10.3389/fphys.2020.00056
- 17. Kawtharany L, Bessueille L, Issa H, Hamade E, Zibara K, Magne D. Inflammation and Microcalcification: A Never-Ending Vicious Cycle in Atherosclerosis? *Journal of Vascular Research*. 2022;59:137-150. doi: 10.1159/000521161
- 18. Hansson GK, Libby P, Tabas I. Inflammation and plaque vulnerability. *J Intern Med*. 2015;278:483-493. doi: 10.1111/joim.12406
- 19. Tzolos E, Dweck MR. ¹⁸F-Sodium Fluoride (¹⁸F-NaF) for Imaging Microcalcification Activity in the Cardiovascular System. Arteriosclerosis, *Thrombosis, and Vascular Biology*. 2020;40:1620-1626. doi: doi:10.1161/ATVBAHA.120.313785
- 20. Sriranjan RS, Tarkin JM, Evans NR, Le EPV, Chowdhury MM, Rudd JHF. Atherosclerosis imaging using PET: Insights and applications. *British Journal of Pharmacology*. 2021;178:2186-2203. doi: htps://doi.org/10.1111/bph.14868

- 21. Høilund-Carlsen PF, Sturek M, Alavi A, Gerke O. Atherosclerosis imaging with (18)Fsodium fluoride PET: state-of-the-art review. *Eur J Nucl Med Mol Imaging*. 2020;47:1538-1551. doi: 10.1007/s00259-019-04603-1
- 22. Blau M, Ganatra R, Bender MA. 18F-fluoride for bone imaging. *Seminars in Nuclear Medicine*. 1972;2:31-37. doi: htps://doi.org/10.1016/S0001-2998(72)80005-9
- 23. Schmid K, McSharry WO, Pameijer CH, Binete JP. Chemical and physicochemical studies on the mineral deposits of the human atherosclerotic aorta. Atherosclerosis. 1980;37:199-210. doi: htps://doi.org/10.1016/0021-9150(80)90005-2
- 24. Bischetti S, Scimeca M, Bonanno E, Federici M, Anemona L, Menghini R, Casella S, Cardellini M, Ippoliti A, Mauriello A. Carotid plaque instability is not related to quantity but to elemental composition of calcification. *Nutr Metab Cardiovasc Dis.* 2017;27:768-774. doi: 10.1016/j.numecd.2017.05.006
- 25. Irkle A, Vesey AT, Lewis DY, Skepper JN, Bird JL, Dweck MR, Joshi FR, Gallagher FA, Warburton EA, Bennett MR, et al. Identifying active vascular microcalcification by (18)F-sodium fluoride positron emission tomography. *Nat Commun*. 2015;6:7495. doi: 10.1038/ncomms8495
- 26. Derlin T, Richter U, Bannas P, Begemann P, Buchert R, Mester J, Klutmann S. Feasibility of 18F-sodium fluoride PET/CT for imaging of atherosclerotic plaque. *J Nucl Med*. 2010;51:862-865. doi: 10.2967/jnumed.110.076471
- 27. Morbelli S, Fiz F, Piccardo A, Picori L, Massollo M, Pestarino E, Marini C, Cabria M, Democrito A, Citadini G, et al. Divergent determinants of 18F–NaF uptake and visible calcium deposition in large arteries: relationship with Framingham risk score. The *International Journal of Cardiovascular Imaging*. 2014;30:439-447. doi: 10.1007/s10554-013-0342-3
- 28. Fiz F, Morbelli S, Piccardo A, Bauckneht M, Ferrarazzo G, Pestarino E, Cabria M, Democrito A, Riondato M, Villavecchia G, et al. ¹⁸F-NaF Uptake by Atherosclerotic Plaque on PET/CT Imaging: Inverse Correlation Between Calcification Density and Mineral Metabolic Activity. *J Nucl Med*. 2015;56:1019-1023. doi: 10.2967/jnumed.115.154229
- 29. Mayer M, Borja AJ, Hancin EC, Auslander T, Revheim ME, Moghbel MC, Werner TJ, Alavi A, Rajapakse CS. Imaging Atherosclerosis by PET, With Emphasis on the Role of

> FDG and NaF as Potential Biomarkers for This Disorder. *Front Physiol*. 2020;11:511391. doi: 10.3389/fphys.2020.511391

- 30. Bhakta S WE, Evans NR. 18F-Sodium Fluoride Uptake on PET/CT in Symptomatic versus Asymptomatic Atherosclerotic Disease: a Meta-Analysis. PROSPERO: International prospective register of systematic reviews. www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=42023451363. 2023.
- 31. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ*. 2021;372:n71. doi: 10.1136/bmj.n71
- 32. Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). In: Higgins JPT TJ, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, ed. Available from www.training.cochrane.org/handbook.: Cochrane; 2023.
- 33. ROBINS-E Development Group (Higgins J MR, Rooney A, Taylor K, Thayer K, Silva R, Lemeris C, Akl A, Arroyave W, Bateson T, Berkman N, Demers P, Forastiere F, Glenn B, Hróbjartsson A, Kirrane E, LaKind J, Luben T, Lunn R, McAleenan A, McGuinness L, Meerpohl J, Mehta S, Nachman R, Obbagy J, O'Connor A, Radke E, Savović J, Schubauer-Berigan M, Schwingl P, Schunemann H, Shea B, Steenland K, Stewart T, Straif K, Tilling K, Verbeek V, Vermeulen R, Viswanathan M, Zahm S, Sterne J). Risk Of Bias In Non-randomized Studies - of Exposure (ROBINS-E). Launch version, 20 June 2023. Available from: https://www.riskofbias.info/welcome/robins-e-tool.
- 34. McGrath S, Katzenschlager S, Zimmer AJ, Seitel A, Steele R, Benedetti A. Standard error estimation in meta-analysis of studies reporting medians. *Stat Methods Med Res*. 2023;32:373-388. doi: 10.1177/09622802221139233
- 35. Viechtbauer W. Conducting meta-analyses in R with the metafor package. *Journal of StaHsHcal SoLware*. 2010;36:1-48. doi: htps://doi.org/10.18637/jss.v036.i03
- 36. McGrath S ZX, Katzenschlager S, Ozturk O, Steele R, Benedetti A. *metamedian: Meta-Analysis of Medians; R package version 1.1.0*. 2023.
- 37. Haddaway NR, Page MJ, Pritchard CC, McGuinness LA. PRISMA2020: An R package and Shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and Open Synthesis. *Campbell Syst Rev*. 2022;18:e1230. doi: 10.1002/cl2.1230
- 38. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016;5:210. doi: 10.1186/s13643-016-0384-4
- 39. Kaczynski J, Sellers S, Seidman MA, Syed M, Dennis M, McNaught G, Jansen M, Semple SI, Alcaide-Corral C, Tavares AAS, et al. (18)F-NaF PET/MRI for Detection of Carotid Atheroma in Acute Neurovascular Syndrome. *Radiology*. 2022;305:137-148. doi: 10.1148/radiol.212283
- 40. Moss A, Daghem M, Tzolos E, Meah MN, Wang K-L, Bularga A, Adamson PD, Kwiecinski J, Fletcher A, Dawson D, et al. Coronary Atherosclerotic Plaque Activity and Future Coronary Events. *JAMA Cardiology*. 2023;8:755-764. doi: 10.1001/jamacardio.2023.1729
- 41. Bucerius J, Hyafil F, Verberne HJ, Slart RHJA, Lindner O, Sciagra R, Agostini D, Übleis C, Gimelli A, Hacker M, on behalf of the Cardiovascular Commitee of the European Association of Nuclear M. Position paper of the Cardiovascular Committee of the European Association of Nuclear Medicine (EANM) on PET imaging of atherosclerosis. *European Journal of Nuclear Medicine and Molecular Imaging*. 2016;43:780-792. doi: 10.1007/s00259-015-3259-3
- 42. Saba L, Loewe C, Weikert T, Williams MC, Galea N, Budde RPJ, Vliegenthart R, Velthuis BK, Francone M, Bremerich J, et al. State-of-the-art CT and MR imaging and assessment of atherosclerotic carotid artery disease: standardization of scanning protocols and measurements-a consensus document by the European Society of Cardiovascular Radiology (ESCR). *Eur Radiol*. 2023;33:1063-1087. doi: 10.1007/s00330-022-09024-7
- 43. Kaul P, Douglas PS. Atherosclerosis Imaging. *Circulation: Cardiovascular Imaging*. 2009;2:150-160. doi: doi:10.1161/CIRCIMAGING.109.850263
- 44. Evans NR, Tarkin JM, Le EP, Sriranjan RS, Corovic A, Warburton EA, Rudd JH. Integrated cardiovascular assessment of atherosclerosis using PET/MRI. The British *Journal of Radiology*. 2020;93:20190921. doi: 10.1259/bjr.20190921
- 45. McKenney-Drake ML, Moghbel MC, Paydary K, Alloosh M, Houshmand S, Moe S, Salavati A, Sturek JM, Territo PR, Weaver C, et al. (18)F-NaF and (18)F-FDG as molecular probes in the evaluation of atherosclerosis. *Eur J Nucl Med Mol Imaging*. 2018;45:2190-2200. doi: 10.1007/s00259-018-4078-0
- 46. Bing R. SALTIRE II: Bisphosphonates and RANKL Inhibition in Aortic Stenosis. ClinicalTrials.gov. htps://clinicaltrials.gov/study/NCT02132026. 2014.
- 47. Montanaro M, Scimeca M, Anemona L, Servadei F, Giacobbi E, Bonfiglio R, Bonanno E, Urbano N, Ippoliti A, Santeusanio G, et al. The Paradox Effect of Calcification in Carotid Atherosclerosis: Microcalcification is Correlated with Plaque Instability. *Int J Mol Sci*. 2021;22. doi: 10.3390/ijms22010395
- 48. Dweck MR, Joshi NV, Jenkins W, Jones C, Chow MWL, Fletcher A, van Beek EJR, Boon NA, Rudd JHF, Newby DE. Assessment of calcification and inflammation with positron emission tomography in aortic stenosis and atherosclerosis. The Lancet. 2013;381:S11. doi: 10.1016/S0140-6736(13)60451-1
- 49. Joshi NV, Vesey AT, Williams MC, Shah AS, Calvert PA, Craighead FH, Yeoh SE, Wallace W, Salter D, Fletcher AM, et al. 18F-fluoride positron emission tomography for identification of ruptured and high-risk coronary atherosclerotic plaques: a prospective clinical trial. *Lancet*. 2014;383:705-713. doi: 10.1016/S0140-6736(13)61754-7
- 50. Quirce R, Martinez-Rodriguez I, Banzo I, Jimenez-Bonilla J, Martinez-Amador N, Ibanez-Bravo S, Lopez-Defillo J, Jimenez-Alonso M, Revilla MA, Carril JM. New insight of functional molecular imaging into the atheroma biology: 18F-NaF and 18F-FDG in symptomatic and asymptomatic carotid plaques after recent CVA. Preliminary results. *Clin Physiol Funct Imaging*. 2016;36:499-503. doi: 10.1111/cpf.12254
- 51. Vesey AT, Jenkins WS, Irkle A, Moss A, Sng G, Forsythe RO, Clark T, Roberts G, Fletcher A, Lucatelli C, et al. (18)F-Fluoride and (18)F-Fluorodeoxyglucose Positron Emission Tomography After Transient Ischemic Attack or Minor Ischemic Stroke: Case-Control Study. *Circ Cardiovasc Imaging*. 2017;10:e004976. doi: 10.1161/CIRCIMAGING.116.004976
- 52. Andrews J, Moss A, Doris M, Pawade T, Adamson P, MacNaught G, Lucatelli C, Newby D, Dweck M. 18 18F-flouride pet MR in valvular and coronary heart disease; a pilot investigational study. *Heart*. 2018;104:A12-A12. doi: 10.1136/heartjnl-2018-BCVI.33
- 53. Marchesseau S, Seneviratna A, Sjoholm AT, Qin DL, Ho JXM, Hausenloy DJ, Townsend DW, Richards AM, Totman JJ, Chan MYY. Hybrid PET/CT and PET/MRI imaging of vulnerable coronary plaque and myocardial scar tissue in acute myocardial infarction. *J Nucl Cardiol*. 2018;25:2001-2011. doi: 10.1007/s12350-017-0918-8
- 54. Sood A, JOIS A, Singhal M, Mital B, Manoj R, Rana N, RAWAT D, Kasinadhuni G, Krisnappa D. Role of ¹⁸F-NaF PET/CT based imaging of atherosclerotic plaques in patients with myocardial infarction and chronic stable angina. *Journal of Nuclear Medicine*. 2018;59:1509-1509.
- 55. Chowdhury MM, Tarkin JM, Albaghdadi MS, Evans NR, Le EPV, Berrett TB, Sadat U, Joshi FR, Warburton EA, Buscombe JR, et al. Vascular Positron Emission Tomography and Restenosis in Symptomatic Peripheral Arterial Disease: A Prospective Clinical Study. *JACC Cardiovasc Imaging*. 2020;13:1008-1017. doi: 10.1016/j.jcmg.2019.03.031
- 56. Evans NR, Tarkin JM, Chowdhury MM, Le EPV, Coughlin PA, Rudd JHF, Warburton EA. Dual-Tracer Positron-Emission Tomography for Identification of Culprit Carotid Plaques and Pathophysiology In Vivo. *Circ Cardiovasc Imaging*. 2020;13:e009539. doi: 10.1161/CIRCIMAGING.119.009539
- 57. Cocker MS, Spence JD, Hammond R, Wells G, deKemp RA, Lum C, Adeeko A, Yaffe MJ, Leung E, Hill A, et al. [(18)F]-NaF PET/CT Identifies Active Calcification in Carotid Plaque. *JACC Cardiovasc Imaging*. 2017;10:486-488. doi: 10.1016/j.jcmg.2016.03.005
- 58. Hop H, de Boer SA, Reijrink M, Kamphuisen PW, de Borst MH, Pol RA, Zeebregts CJ, Hillebrands JL, Slart R, Boersma HH, et al. (18)F-sodium fluoride positron emission tomography assessed microcalcifications in culprit and non-culprit human carotid plaques. *J Nucl Cardiol*. 2019;26:1064-1075. doi: 10.1007/s12350-018-1325-5
- 59. Kim JM, Lee ES, Park KY, Seok JW, Kwon OS. Analysis of (18)F-Fluorodeoxyglucose and (18)F-Fluoride Positron Emission Tomography in Korean Stroke Patients with Carotid Atherosclerosis. *J Lipid Atheroscler*. 2019;8:232-241. doi: 10.12997/jla.2019.8.2.232
- 60. Mechtouff L, Sigovan M, Douek P, Costes N, Le Bars D, Mansuy A, Haesebaert J, Bani-Sadr A, Tordo J, Feugier P, et al. Simultaneous assessment of microcalcifications and morphological criteria of vulnerability in carotid artery plaque using hybrid (18)F-NaF PET/MRI. *J Nucl Cardiol*. 2022;29:1064-1074. doi: 10.1007/s12350-020-02400-0

Table 1 Included study characteristics for studies comparing symptomatic to asymptomatic disease between arteries in the same participant

Table 2 Included study characteristics for studies comparing symptomatic to asymptomatic disease within and between participants

It is made available under a [CC-BY-ND 4.0 International license](http://creativecommons.org/licenses/by-nd/4.0/) .

Embase <1996 to 2023 Week 30>

Ovid MEDLINE(R) and Epub Ahead of Print, In-Process, In-Data-Review & Other Non-Indexed Citations, Daily and Versions <1946 to August 02, 2023>

- $\mathbf{1}$ (18F* or NaF or \$F-NaF*).ti,ab.
- $\overline{2}$ (PET or positron*).ti,ab.
- $\overline{\mathbf{3}}$ (athero* or acute or microcalcif* or plaque).ti,ab.
- $\overline{4}$ (culprit or symptom* or active).ti,ab.
- 1 and 2 and 3 and 4 5
- (editorial* or case report* or review* or meta-analysis).pt. 6
- $\overline{7}$ 5 not 6

Figure 1 Search strategy performed for systematic review and meta-analysis

Figure 2 Funnel plot of studies included in Table 1

Figure 3 Funnel plot of studies included in Table 2

Figure 4 PRISMA diagram of systema7c review search synthesis

Figure 5 Forest Plot of included studies summarising data comparing symptomatic and asymptomatic atherosclerotic disease within individuals. SMD = *standardized mean difference, CI = confidence intervals*

Figure 6 Forest Plot of included studies summarizing data comparing symptomatic and asymptomatic atherosclerotic disease within individuals. SMD = standardized mean difference, CI = confidence intervals

Supplementary Figure 1 - Summary plot of Risk of Bias assessment using ROBINS-E (Risk Of Bias In Non-randomized Studies - of Exposures) tool